SCHEMBL1534526

SCHEMBL1534526

CC(C)(C)OC(=O)NC1(c2ccc(-c3c(-c4ccccc4)oc4c(F)cccc4c3=O)cc2)CCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 2/20 0.40
AKT2 P31751 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.38
MAPT P10636 1/20 0.35
PDE2A O00408 3/20 0.34
ALDH1A1 P00352 2/20 0.34
LMNA P02545 2/20 0.34
SCN9A Q15858 1/20 0.34
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
KIT P10721 1/20 0.34
TACR3 P29371 1/20 0.33
HTR1A P08908 2/20 0.33
ADRA1A P35348 2/20 0.33
ADRA1D P25100 1/20 0.33
ADRA1B P35368 1/20 0.33
CYP3A4 P08684 2/20 0.33
MEN1 O00255 1/20 0.33
GLA P06280 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1534702 0.90 AKT1 (0.40) AKT1AKT2SMN1; SMN2MAPTALDH1A1
SCHEMBL1534322 0.90 AKT1 (0.42) AKT1AKT2ALDH1A1LMNASCN9A
SCHEMBL1534455 0.90 AKT1 (0.44) AKT1AKT2MAPTPDE2AALDH1A1
SCHEMBL1534659 0.88 AKT1 (0.41) AKT1AKT2SMN1; SMN2MAPTALDH1A1
SCHEMBL1534863 0.88 AKT1 (0.43) AKT1AKT2MAPTPDE2AALDH1A1
SCHEMBL12274135 0.87 AKT1 (0.42) AKT1AKT2MAPTPDE2AALDH1A1
SCHEMBL12273689 0.87 AKT1 (0.39) AKT1AKT2SMN1; SMN2MAPTPDE2A
SCHEMBL1534768 0.87 AKT1 (0.39) AKT1AKT2PDE2AALDH1A1LMNA
SCHEMBL1534875 0.87 AKT1 (0.42) AKT1AKT2SMN1; SMN2MAPTPDE2A
SCHEMBL1534480 0.87 AKT1 (0.41) AKT1AKT2MAPTPDE2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546376-B2 Pharmaceutical compounds ALMAC DISCOVERY LIMITED (GB) 2013-10-01 US disclosed
US-20120238541-A1 PHARMACEUTICAL COMPOUNDS ALMAC DISCOVERY LIMITED (GB) 2012-09-20 US disclosed
EP-2473495-A1 PHARMACEUTICAL COMPOUNDS Almac Discovery Limited (GB) 2012-07-11 EP disclosed
WO-2011033265-A1 PHARMACEUTICAL COMPOUNDS ALMAC DISCOVERY LIMITED (GB) 2011-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238541-A1 PHARMACEUTICAL COMPOUNDS PIK3CA, PLK1, MTOR AKT1 6/4885AKT2 4/4885SMN1; SMN2 2863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.